Elevance Health, Inc. (ELV)
NYSE: ELV · Real-Time Price · USD
294.43
+1.95 (0.67%)
At close: Aug 13, 2025, 4:00 PM
294.00
-0.43 (-0.15%)
Pre-market: Aug 14, 2025, 9:00 AM EDT
Elevance Health Stock Forecast
Stock Price Forecast
According to 14 professional analysts, the 12-month price target for Elevance Health stock ranges from a low of $297 to a high of $615. The average analyst price target of $416.86 forecasts a 41.58% increase in the stock price over the next year.
Price Target: $416.86 (+41.58%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Elevance Health stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 | Aug '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 5 | 5 | 5 | 4 | 4 |
| Buy | 9 | 8 | 8 | 7 | 8 | 8 |
| Hold | 1 | 2 | 2 | 2 | 3 | 3 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 15 | 15 | 15 | 14 | 15 | 15 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Baird | Baird | Hold Maintains $492 → $297 | Hold | Maintains | $492 → $297 | +0.87% | Jul 25, 2025 |
| JP Morgan | JP Morgan | Buy Maintains $472 → $384 | Buy | Maintains | $472 → $384 | +30.42% | Jul 22, 2025 |
| Barclays | Barclays | Buy Maintains $358 → $327 | Buy | Maintains | $358 → $327 | +11.06% | Jul 22, 2025 |
| Argus Research | Argus Research | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | Jul 21, 2025 |
| UBS | UBS | Strong Buy Maintains $484 → $435 | Strong Buy | Maintains | $484 → $435 | +47.74% | Jul 18, 2025 |
Financial Forecast
Revenue This Year
198.61B
from 176.81B
Increased by 12.33%
Revenue Next Year
210.05B
from 198.61B
Increased by 5.76%
EPS This Year
34.75
from 25.68
Increased by 35.31%
EPS Next Year
39.69
from 34.75
Increased by 14.22%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 209.0B | 223.6B | 238.6B | ||
| Avg | 198.6B | 210.0B | 223.3B | ||
| Low | 191.1B | 196.5B | 213.2B |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 18.2% | 12.6% | 13.6% | ||
| Avg | 12.3% | 5.8% | 6.3% | ||
| Low | 8.1% | -1.0% | 1.5% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 36.33 | 43.68 | 50.74 | ||
| Avg | 34.75 | 39.69 | 45.84 | ||
| Low | 33.09 | 37.61 | 42.39 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 41.5% | 25.7% | 27.8% | ||
| Avg | 35.3% | 14.2% | 15.5% | ||
| Low | 28.9% | 8.2% | 6.8% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.